Fascioscapulohumeral muscular dystrophy type 2

Clinical trials for Fascioscapulohumeral muscular dystrophy type 2 explained in plain language.

Never miss a new study

Get alerted when new Fascioscapulohumeral muscular dystrophy type 2 trials appear

Sign up with your email to follow new studies for Fascioscapulohumeral muscular dystrophy type 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Not yet finished but already full! 1 Completed 1

Hope for FSHD: new drug enters final stage of testing

Disease control Recruiting now

This phase 3 trial tests an experimental drug called AOC 1020 in 200 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. Participants receive either the drug or a placebo by IV infusion. The study measures muscle…

Matched conditions: FASCIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 2

Phase 3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control

Last updated Jul 29, 2026 00:00 UTC

Fascioscapulohumeral muscular dystrophy type 2

Get alerted when new Fascioscapulohumeral muscular dystrophy type 2 trials appear

Hope for FSHD: new drug enters final stage of testing